Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control

MLA

Huang, Shih-Hao, et al. Front-Line Treatment of Ceritinib Improves Efficacy over Crizotinib for Asian Patients with Anaplastic Lymphoma Kinase Fusion NSCLC: The Role of Systemic Progression Control. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1363082451&authtype=sso&custid=ns315887.

APA

Huang, S.-H., Huang, A. C.-C., Wang, C.-C., Chang, W.-C., Liu, C.-Y., Pavlidis, S., Ko, H.-W., Chung, F.-T., Hsu, P.-C., Guo, Y., Kuo, C.-H. S., & Yang, C.-T. (2019). Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.

Chicago

Huang, Shih-Hao, Allen Chung-Cheng Huang, Chin-Chou Wang, Wen-Chen Chang, Chien-Ying Liu, Stelios Pavlidis, Ho-Wen Ko, et al. 2019. “Front-Line Treatment of Ceritinib Improves Efficacy over Crizotinib for Asian Patients with Anaplastic Lymphoma Kinase Fusion NSCLC: The Role of Systemic Progression Control.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1363082451&authtype=sso&custid=ns315887.